Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Authors:

Abstract
No abstract available
Funding Information
  • F. Hoffmann-La Roche

This publication has 21 references indexed in Scilit: